Danaher (NYSE:DHR) added ~8% in the premarket on Tuesday as the U.S. life sciences company reported its Q3 2025 financials, beating the analyst forecasts, thanks mainly to its Diagnostics unit.
The Washington, DC-based healthcare giant generated $1.89 of non-GAAP earnings per share, indicating ~11% YoY improvement as its revenue expanded ~4% YoY to $6.1B, beating the consensus by $0.17 and $50M, respectively.
Danaher’s (NYSE:DHR) Biotechnology and Diagnostics divisions outperformed, adding $1.80B and $2.46B to the topline with ~9% YoY and ~4% YoY in sales growth, exceeding the consensus of $1.78B and $2.41B, respectively, according to Bloomberg data.
Meanwhile, revenue from its Life Sciences segment remained flat at $1.79B, falling short of the $1.81B projected by analysts.
Notably, the company’s operating profit surged ~21% YoY to $1.2B as the Diagnostics unit’s operating income rose ~8% YoY to $665M, exceeding the $565.3M consensus, and the Life Sciences unit added $222M compared to the $242.3M projected by analysts.
DHR’s adjusted operating margin improved to 27.9% from 25.6% in the prior year period, and its adjusted EBITDA rose ~6% YoY to $1.9B, ahead of $1.7B in the consensus.
Looking ahead, the company reaffirmed its full-year outlook for adjusted diluted net earnings per common share at $7.70 to $7.80, in line with the Street forecasts, assuming a low-single-digit growth projection in non-GAAP core revenue.